Compare Biogen Inc (BIIB) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares MSCI Australia ETF — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while iShares MSCI Australia ETF trades at $28.71. Which is the better fit depends on your goals.
| BIIB | EWA | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $30.26 |
52-Week Low | $122.68 | $24.95 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
EWA trades at $28.35, down 0.35% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 57.64. Recent dividend announcement of $0.40 payable June 2026 provides income potential. Support levels cluster around $28 with resistance at $29.
Outlook remains cautiously optimistic given technical strength, though limited fundamental data availability warrants careful evaluation. Key catalysts include dividend payments and broader market trends. Risks include market volatility and Australia-specific economic factors affecting performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
